• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Introduction to Zinc Cyclohexylbutyrate (CAS No. 38582-18-2)

Zinc cyclohexylbutyrate, a compound with the chemical identifier CAS No. 38582-18-2, has garnered significant attention in the field of pharmaceutical and biochemical research due to its unique properties and potential applications. This compound, characterized by its zinc cation and cyclohexylbutyrate anion, represents a fascinating subject of study for researchers exploring novel therapeutic agents and biochemical modulators.

The structural composition of Zinc cyclohexylbutyrate lends itself to various biological interactions, making it a promising candidate for further investigation. The cyclohexylbutyrate moiety is known for its ability to interact with biological targets in a manner that can modulate cellular processes. This interaction potential has sparked interest in exploring its role in drug development, particularly in the context of anti-inflammatory and analgesic therapies.

Recent studies have begun to uncover the pharmacological properties of Zinc cyclohexylbutyrate. Research indicates that this compound may exhibit anti-inflammatory effects by inhibiting key pro-inflammatory cytokines and enzymes. The zinc component, in particular, is recognized for its ability to modulate enzymatic activity and cellular signaling pathways, which could contribute to its therapeutic potential.

In addition to its anti-inflammatory properties, Zinc cyclohexylbutyrate has shown promise in preliminary studies as a potential analgesic agent. Its ability to interact with pain-signaling pathways suggests that it may offer relief from chronic pain conditions without the side effects associated with some traditional pain medications. This makes it an attractive option for further development in the field of pain management.

The synthesis and characterization of Zinc cyclohexylbutyrate have been refined through advanced chemical methodologies, ensuring high purity and consistency for research applications. The compound’s stability under various conditions makes it suitable for both in vitro and in vivo studies, providing researchers with a reliable tool for exploring its biological effects.

One of the most intriguing aspects of Zinc cyclohexylbutyrate is its potential role in modulating neuroinflammatory processes. Studies have suggested that it may interact with microglial cells, which are key players in neuroinflammation, thereby reducing inflammation and protecting against neuronal damage. This finding opens up new avenues for research into neurodegenerative diseases where inflammation plays a significant role.

The pharmacokinetic profile of Zinc cyclohexylbutyrate is another area of active investigation. Understanding how the compound is absorbed, distributed, metabolized, and excreted is crucial for optimizing its therapeutic use. Preliminary data suggest that it exhibits moderate bioavailability and a favorable half-life, making it a candidate for repeated dosing regimens.

Furthermore, the safety profile of Zinc cyclohexylbutyrate has been evaluated through preliminary toxicology studies. These studies indicate that the compound is well-tolerated at doses relevant to therapeutic use, with minimal adverse effects observed. However, further extensive toxicity studies are necessary to fully assess its safety profile before clinical trials can be considered.

The future direction of research on Zinc cyclohexylbutyrate includes exploring its potential in combination therapies. By pairing it with other compounds that target different aspects of disease pathology, researchers hope to enhance its therapeutic efficacy. This approach could lead to more comprehensive treatment strategies for conditions such as chronic pain and neuroinflammatory disorders.

In conclusion, Zinc cyclohexylbutyrate (CAS No. 38582-18-2) represents a promising compound with significant potential in pharmaceutical applications. Its unique structural properties and demonstrated biological effects make it an attractive candidate for further research and development. As our understanding of its mechanisms of action continues to grow, so too will its potential as a therapeutic agent.

• 6243-10-3(Cyclohexyl hexanoate)
• 16429-21-3(2-Oxepanone, 7-hexyl-)
• 10018-78-7(4-(Cyclohexyloxy)-4-oxobutanoic acid)
• 1551-44-6(cyclohexyl butyrate)
• 1551-43-5(Cyclohexyl valerate)
• 32539-85-8(Pentadecanolide)
• 108-63-4(Dicapryl Adipate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)